Clinical TrialDepressive DisordersCompleted

Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI (ESKETAM)

This observational trial (n=13) was conducted by the University Hospital, Strasbourg, France. The study aimed to assess the tolerance and potential synergistic effect of combining intranasal esketamine with non-selective MAOIs in patients with depression and anxiety disorders.

Target Enrollment
13 participants
Study Type
Phase NA observational
Design
Non-randomized

Detailed Description

Published data on combinations of ketamine/esketamine with MAOIs are sparse and to our knowledge no data exist for intranasal esketamine; this study shares clinical experience from a specialised centre.

Retrospective case-only series of 13 adults treated with intranasal esketamine between 2018-01-01 and 2022-03-01 assessing tolerability and potential synergistic effects when combined with non-selective MAOIs; data reuse required patient consent.

Participants

Ages
18 – 99
Sexes
Male & Female

Inclusion Criteria

  • Inclusion criteria:
  • Major subject.
  • Having been treated with intranasal esketamine between 01/01/2018 and 01/03/2022.
  • Not objecting to the reuse of their data for scientific research purposes.

Exclusion Criteria

  • Exclusion Criteria:
  • Subject who has expressed opposition to the reuse of their data for scientific research purposes.

Study Details

  • Status
    Completed
  • Phase
    Phase NA
  • Type
    observational
  • Design
    Non-randomized
  • Target Enrollment13 participants
  • Timeline
    Start: 2022-04-11
    End: 2022-12-11
  • Topic
    Depressive Disorders

Locations

Service de physiologie - Explorations fonctionnelles - CHU de Strasbourg - France — Strasbourg, France

Your Library